Lexaria Bioscience Corp.
LEXX evidence brief
What we can confirm
- Market Cap:
- $8.4M
What it means
What to watch
Prepared research question
What matters most for LEXX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LEXX
Lexaria Bioscience Corp. (LEXX) is a biotechnology company developing its DehydraTECH drug delivery platform to improve the oral bioavailability of drugs, with primary research programs focused on GLP-1 drugs for diabetes/weight loss and CBD for hypertension.
Key risk: Zero revenue, ongoing losses
Market Cap
$8.4M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of May 31, 2026.
Tracking 1 clinical trial for Lexaria Bioscience Corp..
Lexaria Bioscience Corp. (LEXX) is a biotechnology company developing its DehydraTECH drug delivery platform to improve the oral bioavailability of drugs, with primary research programs focused on GLP-1 drugs for diabetes/weight loss and CBD for hypertension.
- Cash & equivalents of $3.5M as of 2026-05-31 [sec]
- Total revenue of $0.0M and net income of -$2.0M for the period ending 2026-05-31 [sec]
- Shareholders' equity of $4.7M as of 2026-05-31 [sec]
- FDA agreed to a 505(b)(2) NDA regulatory pathway for DehydraTECH-CBD for hypertension; IND received a Study May Proceed letter on February 29, 2024 [sec_mda · as of 2026-07-13]
- Positive final results from GLP-1-H25-5 human pilot study comparing oral DehydraTECH liraglutide to injected Saxenda, achieving primary safety and tolerability endpoint [sec_mda · as of 2026-07-13]
What works
- DehydraTECH platform has shown ability to improve oral bioavailability of multiple drug classes, including GLP-1 drugs and CBD, with successful human and animal testing results [sec_mda · as of 2026-07-13]
- FDA has agreed to a 505(b)(2) NDA regulatory pathway for DehydraTECH-CBD for hypertension, providing a potentially streamlined approval route [sec_mda · as of 2026-07-13]
- Company has an active material transfer agreement with a pharmaceutical company (PharmaCO) that includes a temporary exclusive license, indicating external commercial interest [sec_mda · as of 2026-07-13]
What to weigh
- Company has zero revenue and continues to incur operating losses and negative cash flows, with net income of -$2.0M for the period ending 2026-05-31 [sec]
- Cash position is limited ($3.5M as of 2026-05-31) and the company has historically funded operations primarily through stock sales, with no guarantee of future funding [sec_mda · as of 2026-07-13]
- The hypertension Phase 1b IND study (HYPER-H23-1) has not yet commenced due to funding constraints, despite receiving FDA clearance in early 2024 [sec_mda · as of 2026-07-13]
- All primary clinical programs are in early stages (preclinical or Phase 1), with no approved products or near-term revenue expected [sec_mda · as of 2026-07-13]
From the filings
Quoted directly from source documents.
FDA agreed to 505(b)(2) pathway for DehydraTECH-CBD hypertension program
“The FDA confirmed that it had agreed with Lexaria's proposal to pursue a 505(b)(2) new drug application ("NDA") regulatory pathway for our program.”
SEC MD&A · July 13, 2026
Positive results from GLP-1-H25-5 pilot study comparing oral DHT-LIR to injected Saxenda
“Announced positive final results from its GLP-1-H25-5 Human Pilot Study comparing oral DehydraTECH enhanced liraglutide ("DHT-LIR") to the commercially available injected Saxenda® liraglutide. These results demonstrated achievement of the primary safety and tolerability endpoint for DHT-LIR”
SEC MD&A · July 13, 2026
Company expects continued operating losses and negative cash flows
“we anticipate that we will continue to incur operating losses and negative cash flows for the foreseeable future covering 2026 and beyond.”
SEC MD&A · July 13, 2026
Catalyst timeline
- 2024-12-04 · Phase 1B study start (DehydraTECH-CBD + GLP-1 agonists in diabetic/obese participants) — This is a Phase 1B, randomized, open-label, active-controlled study; watch for initial safety and PK data readouts.
Risks & what to watch (4)›
Key risks
- Zero revenue, ongoing losses — Company reported $0.0M revenue and -$2.0M net income as of 2026-05-31, with no near-term product sales expected [sec]
- Limited cash runway — Cash of $3.5M as of 2026-05-31 may be insufficient to fund planned R&D and clinical studies without additional financing [sec]
- Funding-dependent clinical start — Hypertension Phase 1b study (HYPER-H23-1) has not started due to funding needs, despite FDA clearance since Feb 2024 [sec_mda · as of 2026-07-13]
- Early-stage pipeline — All programs are preclinical or Phase 1; no approved products or guaranteed regulatory success [sec_mda · as of 2026-07-13]
What to watch
- Initiation and results of the Phase 1b hypertension study HYPER-H23-1, which has FDA clearance but awaits funding [sec_mda · as of 2026-07-13]
- Outcome of Animal Study #2 (GLP-1-A26-2) testing DehydraTECH with retatrutide and amycretin, with results expected in Q4 fiscal 2026 [sec_mda · as of 2026-07-13]
- Progress of the five-week human clinical study comparing oral DehydraTECH-semaglutide to Wegovy, announced April 2026 [news · published 2026-04-01]
- Any updates on the material transfer agreement with PharmaCO, including potential strategic partnership or licensing decisions [sec_mda · as of 2026-07-13]
Sources: Catalysts · News · SEC MD&A · Generated October 3, 2026 · How we verify sources →
Run Lexaria Bioscience Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lexaria Bioscience Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 1.5%
- Days to cover
- 1.5
- Shares short
- 346,201
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LEXX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lexaria Bioscience Corp.?
Lexaria Bioscience Corp. (LEXX) is a biotechnology company developing its DehydraTECH drug delivery platform to improve the oral bioavailability of drugs, with primary research programs focused on GLP-1 drugs for diabetes/weight loss and CBD for hypertension.
Who is the CEO of Lexaria Bioscience Corp.?
Mr. Richard C. Christopher is the chief executive officer of Lexaria Bioscience Corp. (LEXX).
Where is Lexaria Bioscience Corp. headquartered?
Lexaria Bioscience Corp. (LEXX) is headquartered in Kelowna, BC, Canada.
What therapeutic areas does Lexaria Bioscience Corp. focus on?
Lexaria Bioscience Corp. develops therapies across Oncology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.